Xilio Therapeutics, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Rene Russo
- Full Time Employees
- 64
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 828 Winter Street Waltham MA United States of America 02451
- IPO Date
- Oct 22, 2021
- CIK
- 0001840233
- Website
- xiliotx.com
- Similar Companies
- Business
- Xilio Therapeutics, Inc. is a clinical-stage biotechnology company specializing in the discovery and development of tumor-activated immuno-oncology therapies designed to selectively activate the immune system within the tumor microenvironment to minimize systemic toxicity. Its core product pipeline includes tumor-activated biologics such as masked bispecific antibodies, masked T cell engagers, tumor-activated cytokines, and immune cell engagers, with key investigational candidates including Vilastobart (XTX101), an anti-CTLA-4 monoclonal antibody; XTX301, a tumor-activated interleukin-12 (IL-12); and XTX501, a novel tumor-activated bispecific PD-1/IL-2 therapeutic. The company leverages a proprietary, clinically validated platform technology to optimize therapeutic indices by localizing anti-tumor activity specifically within the tumor microenvironment. Xilio operates primarily in the biotechnology and pharmaceuticals sectors, targeting cancer patients globally, with a focus on solid tumors characterized as immunologically 'cold' or non-responsive to conventional immune checkpoint inhibitors. Founded in 2016 and headquartered in Boston, Massachusetts, Xilio Therapeutics has recently undertaken significant strategic initiatives to advance its clinical pipeline and financial positioning. In February 2025, the company entered into a collaboration, license, and option agreement with AbbVie valued at an upfront payment of $52 million and potential milestone payments and royalties totaling up to $2.1 billion. This partnership centers on the co-development of multiple tumor-activated immunotherapies, including masked T cell engager programs targeting tumor-associated antigens such as PSMA, Claudin 18.2, and STEAP1. Additionally, in March 2024, Xilio granted Gilead Sciences an exclusive global license to develop and commercialize XTX301, underscoring its strategic alliances to accelerate therapeutic development. The company recently initiated Phase 2 clinical trials for XTX301 and continues to advance its masked T cell engager programs, with plans to submit an Investigational New Drug (IND) application for XTX501 in mid-2026. Xilio emphasizes the reduction of immune-related adverse events common with existing immuno-oncology agents by employing masking technology that limits systemic exposure and enhances tumor selectivity. Its innovative approach targets difficult-to-treat cancers, aiming to improve patient outcomes by achieving robust anti-tumor immune activation with improved tolerability. The company's present cash runway is projected to extend into early 2026 supported by its latest financing and collaboration revenues. Xilio Therapeutics' commitment to advancing next-generation tumor-activated immunotherapies reflects its position as a pioneering entity within the immuno-oncology sector, seeking to commercialize novel biologics that address unmet needs in oncology treatment worldwide.
Cancer Stocks That Are Advancing the Future of Oncology Care
Xilio Therapeutics, Inc. (XLO) Reports Q1 Loss, Beats Revenue Estimates
Xilio Therapeutics Reports First Quarter 2026 Financial Results and Provides Pipeline and Business Updates
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Xilio Therapeutics Announces New Preclinical Data at AACR Annual Meeting for XTX601, a Masked T Cell Engager Targeting CLDN18.2
Xilio Therapeutics Appoints Cheryl R. Blanchard, Ph.D.
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Xilio Therapeutics (XLO) Upgraded to Buy: What Does It Mean for the Stock?
Cancer Stocks to Buy as Innovation Reshapes Global Oncology Market
Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2025 Financial Results
Xilio Therapeutics to Present New Preclinical Data for its Masked T Cell Engager Program Targeting CLDN18.2 at the American Association for Cancer Research (AACR) Annual Meeting
Xilio Therapeutics Announces 1-for-14 Reverse Stock Split
Xilio Therapeutics to Present at the Leerink Partners Global Healthcare Conference
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Xilio Therapeutics Announces Pricing of Underwritten Offering
Xilio Therapeutics Highlights Upcoming Milestones and Recent Corporate Updates
Head to Head Review: Xilio Therapeutics (NASDAQ:XLO) and Aligos Therapeutics (NASDAQ:ALGS)
Xilio Therapeutics (NASDAQ:XLO) Stock Price Down 0.5% – What’s Next?
Xilio Therapeutics (NASDAQ:XLO) Trading Up 5% – Still a Buy?